Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 18/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 18/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 16/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 16/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 16/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10364959 | 0.94 | CHRM3 (0.36) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL10324357 | 0.93 | PTPN1 (0.39) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL9975796 | 0.93 | PTPN1 (0.39) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL9975695 | 0.93 | CHRM5 (0.35) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL9975678 | 0.93 | CD274 (0.36) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL9941790 | 0.92 | SIGMAR1 (0.37) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL10323778 | 0.92 | CHRM5 (0.35) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL9975717 | 0.92 | ACHE (0.38) | CHRM5CHRM1CHRM2CHRM3 | |
| SCHEMBL9975674 | 0.92 | ALDH1A1 (0.36) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL9941374 | 0.92 | CHRM2 (0.36) | CHRM5CHRM1CHRM2CHRM4CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140322165-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | COCRYSTAL DISCOVERY INC (US) | 2014-10-30 | — | — | US | disclosed |
| US-20140322165-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | COCRYSTAL DISCOVERY INC (US) | 2014-10-30 | — | — | US | disclosed |
| US-20140322165-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | COCRYSTAL DISCOVERY INC (US) | 2014-10-30 | — | — | US | disclosed |
| US-8771665-B2 | Inhibitors of hepatitis C virus polymerase | COCRYSTAL DISCOVERY, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-8771665-B2 | Inhibitors of hepatitis C virus polymerase | COCRYSTAL DISCOVERY, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-8771665-B2 | Inhibitors of hepatitis C virus polymerase | COCRYSTAL DISCOVERY, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20120183496-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | COCRYSTAL DISCOVERY, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120183496-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | COCRYSTAL DISCOVERY, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120183496-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | COCRYSTAL DISCOVERY, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| WO-2012083105-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | COCRYSTAL DISCOVERY, INC. (US) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120183496-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | POLR2A, POLR2B, POLR2E | CHRM5 3426/4885CHRM1 1499/4885CHRM2 2882/4885 |
| US-20140322165-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | POLR2A, POLR2B, POLR2E | CHRM5 3426/4885CHRM1 1499/4885CHRM2 2882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.